Stock listing

NASDAQ:IBIO iBio, Inc. Stock

Home listing (NASDAQ) of iBio, Inc.

Follow iBio, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:IBIO

$0.80 USD -0.05 (-5.7%)

Close on Nov 20, 2026

Past year -19.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.763 – $0.827 USDNov 20, 2026
Volume
3.36M sharesNov 20, 2026
Market cap
$51.45M USDAt the close on Nov 20, 2026 · price × 64.31M shares outstanding
52-week range
$0.675 – $3.82 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$726,570 USDMedian day 436,011 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
iBio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IBIO · Home$0.80 USD-0.048 (-5.7%)3,363,632$0.796$0.827$0.763$0.848Close on Nov 20, 2026
Frankfurt:0JV0€0.714 EUR0.000 (0.0%)—€0.677€0.714€0.677€0.714Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IBIO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.80-0.048-5.7%$0.796$0.827$0.7633,363,632
$0.848+0.10+13.4%$0.75$0.868$0.75842,564
$0.748+0.041+5.9%$0.705$0.762$0.70520,871
$0.707-0.025-3.4%$0.74$0.775$0.675586,955
$0.732-0.03-4.0%$0.786$0.80$0.703451,700
$0.762-0.062-7.5%$0.83$0.832$0.76299,174
$0.824+0.044+5.7%$0.792$0.833$0.77361,180
$0.78-0.015-1.9%$0.795$0.80$0.77221,667
$0.795+0.056+7.6%$0.76$0.828$0.75668,636
$0.739+0.009+1.2%$0.75$0.767$0.713289,400
$0.73-0.07-8.7%$0.775$0.79$0.701694,151
$0.80-0.023-2.9%$0.841$0.85$0.80277,394
$0.824+0.024+3.0%$0.80$0.836$0.79397,317
$0.80+0.031+4.1%$0.80$0.80$0.75307,069
$0.769-0.045-5.5%$0.81$0.811$0.74213,524
$0.814+0.009+1.2%$0.819$0.83$0.777247,599
$0.804+0.037+4.9%$0.77$0.808$0.74280,700
$0.767+0.06+8.5%$0.707$0.774$0.69474,565
$0.707-0.013-1.8%$0.73$0.73$0.686508,951
$0.72-0.06-7.7%$0.77$0.78$0.71653,900
$0.78-0.06-7.1%$0.84$0.85$0.75654,800
$0.84+0.02+2.4%$0.84$0.88$0.84517,900
$0.82+0.06+7.9%$0.76$0.89$0.762,212,300
$0.76-0.01-1.3%$0.76$0.78$0.75354,100
$0.77-0.01-1.3%$0.78$0.80$0.76310,000
$0.780.000.0%$0.75$0.82$0.75348,500
$0.780.000.0%$0.78$0.81$0.731,433,800
$0.78-0.12-13.3%$0.90$0.90$0.771,343,700
$0.90+0.03+3.4%$0.89$0.95$0.88452,100
$0.87-0.05-5.4%$0.92$0.97$0.851,642,000
$0.92-0.09-8.9%$1.00$1.00$0.90684,800
$1.01-0.04-3.8%$1.05$1.06$0.972,707,900
$1.05-0.07-6.3%$1.12$1.15$1.021,207,600
$1.12-0.01-0.9%$1.14$1.18$1.081,126,100
$1.13+0.02+1.8%$1.12$1.15$1.07531,200
$1.11-0.07-5.9%$1.18$1.21$1.10337,900
$1.18+0.01+0.9%$1.19$1.22$1.17227,900
$1.170.000.0%$1.20$1.20$1.16234,300
$1.17-0.02-1.7%$1.19$1.19$1.15295,600
$1.19-0.01-0.8%$1.23$1.24$1.15617,600
$1.20-0.05-4.0%$1.25$1.25$1.19376,300
$1.25-0.08-6.0%$1.32$1.35$1.24363,700
$1.33+0.07+5.6%$1.28$1.37$1.242,092,200
$1.26-0.02-1.6%$1.29$1.31$1.26385,500
$1.28+0.03+2.4%$1.26$1.30$1.24440,600
$1.25+0.07+5.9%$1.25$1.31$1.212,090,500
$1.18-0.01-0.8%$1.19$1.20$1.17406,900
$1.19-0.01-0.8%$1.20$1.22$1.17375,800
$1.20-0.01-0.8%$1.23$1.23$1.20324,000
$1.21-0.02-1.6%$1.24$1.24$1.20184,800
$1.23-0.03-2.4%$1.26$1.26$1.22308,900
$1.26-0.04-3.1%$1.30$1.30$1.25404,600
$1.30-0.01-0.8%$1.31$1.32$1.28190,900
$1.31+0.01+0.8%$1.29$1.33$1.28265,400
$1.30-0.01-0.8%$1.32$1.35$1.29353,500
$1.31+0.05+4.0%$1.26$1.34$1.26310,700
$1.26-0.01-0.8%$1.27$1.30$1.212,232,800
$1.27-0.09-6.6%$1.37$1.37$1.25875,800
$1.36-0.04-2.9%$1.42$1.42$1.34513,500
$1.40-0.03-2.1%$1.43$1.46$1.40374,500
$1.43-0.04-2.7%$1.47$1.47$1.43259,200
$1.47+0.05+3.5%$1.41$1.48$1.41436,011
$1.42-0.01-0.7%$1.45$1.45$1.371514,909
$1.43-0.04-2.7%$1.46$1.50$1.42754,700
$1.47-0.02-1.3%$1.47$1.50$1.441,977,100

Splits

3 splits since 2018 · NASDAQ:IBIO · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
1-for-25Consolidation
1-for-10Consolidation
Ticker
NASDAQ:IBIO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All iBio, Inc. news

iBio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
21 in the last 12 months · 118 in all · newest Nov 16, 2026 · oldest 2019
Decks
21 decks · latest November 2026

Where iBio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IBIO · Home listing · This pageNASDAQUnited StatesUSD
Tradegate:0JV0TradegateGermanyEUR
gettex:0JV0gettexGermanyEUR
BOATS:IBIOBOATSUnited StatesUSD
Munich:0JV0MunichGermanyEUR
Frankfurt:0JV0FrankfurtGermanyEUR
Stuttgart:0JV0StuttgartGermanyEUR

Valuation

EV/sales −21.5× against a median of 8.6×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$23.13M USD
P/E
Loss
EV/sales
−21.5×
EV/EBITDA
Negative EBITDA
Price/book
0.7×
Gross margin
126.9%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
2.01

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
iBio, Inc. · NASDAQ:IBIOUS$51.45M−US$23.13Mn/a−21.5×n/a0.7×n/a0.0×2.01
Boundless Bio, Inc. · NASDAQ:BOLDUS$53.61M−US$9.28Mn/an/an/a0.9×n/a0.0×0.65
Xilio Therapeutics, Inc. · NASDAQ:XLOUS$53.40M−US$62.82Mn/a−1.1×n/a0.8×−20.9%0.1×0.76
Impact BioMedical, Inc. · AMEX:IBOUS$53.31MUS$53.29M33.0×1,402×n/a5.3×n/a0.0×0.06
XBiotech Inc. · NASDAQ:XBITUS$52.74M−US$52.29Mn/an/an/a0.4×n/a0.0×0.52
Bonus Biogroup Ltd. · TASE:BONSUS$52.22MUS$54.52Mn/an/an/an/an/an/an/a
Sirnaomics Ltd. · HKEX:2257US$51.13MUS$69.20Mn/an/an/an/an/an/an/a
Cinclus Pharma Holding AB · OMXSTO:CINPHAUS$51.07MUS$13.13Mn/a3.8×n/a2.6×−765.8%0.0×n/a
Aldeyra Therapeutics, Inc. · NASDAQ:ALDXUS$50.70MUS$9.72Mn/an/an/a1.4×n/a0.0×0.66
Clene Inc. · NASDAQ:CLNNUS$50.69MUS$58.31Mn/a245×n/an/an/an/a1.48
Aptamer Sciences, Inc. · KRX:291650US$49.50MUS$34.66Mn/a8.6×n/a1.6×−215.8%0.0×n/a
Median of the othersUS$51.67MUS$23.90M33.0×8.6×1.4×−215.8%0.0×0.66

Forecasts

8 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
5.69 USD · Analysts' mean
EPS, year to Jun 2027
-0.37 · 9 analysts
Revenue, year to Jun 2027
25K · 8 analysts

Team and board

Officers

OfficerRole
Martin BrennerChief Executive Officer and Chief Scientific Officer
Felipe DuranChief Financial Officer
Marc BanjakChief Legal Officer
Endocrinologist Molly CarrChief Medical Officer
Molly CarrChief Medical Officer

Board

DirectorRole
Chip ClarkChairman of the Board
Alexandra KropotovaDirector
António ParadaDirector
David ArkowitzDirector
Elizabeth StonerDirector
Gary SenderDirector

Events

QuarterResultsShare move
Q1 2027Nov 10, 2026 · After close+5.7%
Q4 2026Aug 28, 2026 · Before open−2.9%
Q3 2026May 13, 2026−3.1%
Q2 2026Feb 10, 2026 · After close−2.6%
Q1 2026Nov 12, 2025−7.3%
Q4 2025Sep 5, 2025 · Before open+3.7%
Q3 2025May 2, 2025 · Before open−1.9%
Q2 2025Feb 10, 2025 · After close−7.3%
Q1 2025Nov 12, 2024 · After close−9.0%
Q4 2024Sep 25, 2024 · After close+7.1%
All 20 quarters
QuarterResultsShare move
Q3 2024May 13, 2024 · After close+3.3%
Q2 2024Feb 9, 2024 · After close+2.5%
Q1 2024Nov 13, 2023 · After close−3.5%
Q4 2023Sep 27, 2023 · After close0.0%
Q3 2023May 15, 2023 · Before open−6.9%
Q2 2023Feb 14, 2023 · After close−3.4%
Q1 2023Oct 11, 2022 · After close−1.6%
Q4 2022Sep 27, 2022 · After close−34.4%
Q3 2022May 12, 2022 · After close−7.4%
Q2 2022Feb 14, 2022 · After close−2.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck29 slidesNovember 2026
Investor Presentation (September 2026)Investor deck29 slidesSeptember 2026
Investor Presentation (March 2026)Investor deck39 slidesMar 9, 2026
Investor Presentation (August 2025)Investor deck34 slidesAug 18, 2025
Investor Presentation (June 2025)Investor deck45 slidesJun 24, 2025
Investor Presentation (April 2025)Investor deck87 slidesApr 8, 2025
Investor Presentation (January 2025)Investor deck81 slidesJan 10, 2025
Investor Presentation (October 2024)Investor deck72 slidesOct 23, 2024
Investor Presentation (June 2024)Investor deck67 slidesJun 3, 2024
Investor Presentation (January 2024)Investor deck66 slidesJan 8, 2024
All 21 decks
DeckKindSlidesDate
Investor Presentation (October 2023)Investor deck53 slidesOct 2, 2023
Investor Presentation (July 2023)Investor deck47 slidesJul 10, 2023
Investor Presentation (April 2023)Investor deck46 slidesApr 24, 2023
Investor Presentation (November 2022)Investor deck33 slidesNov 3, 2022
Investor Presentation (October 2022)Investor deck23 slidesOct 3, 2022
Investor Presentation (May 2022)Investor deck29 slidesMay 16, 2022
Investor Presentation (March 2022)Investor deck30 slidesMar 18, 2022
Investor Presentation (August 2021)Investor deck32 slidesAug 30, 2021
IPO Roadshow (October 2019)IPO roadshow24 slidesOct 11, 2019
IPO Roadshow (June 2018)IPO roadshow24 slidesJun 13, 2018
Noble Financial Sixth Annual Equity Conference ONTRACK 2010Conference25 slidesJun 4, 2010

Open Decks

Financings

RaiseDate
Private placement of shares of common stock (or pre-funded warrants in lieu thereof)
Announced: about US$26M · US$2.35 a share · Leerink Partners +2
Dealers: Leerink Partners (lead), LifeSci Capital (co-lead), Oppenheimer & Co. (co-lead)
Buyers: Frazier Life Sciences
Use of proceeds: Advance preclinical cardiometabolic programs incl. IBIO-610, IBIO-600 and bispecifics, other pipeline assets, working capital and general corporate purposes
Jan 9, 2026
Public offering of pre-funded warrants and accompanying Series G warrants
Closed: US$50M raised · US$0.699 a share · ½ warrant at US$0.7 · Leerink Partners +3
Dealers: Leerink Partners (lead), LifeSci Capital, Oppenheimer & Co., Brookline Capital Markets
Buyers: Balyasny Asset Management; Cormorant Asset Management; Adage Capital Partners LP; Ally Bridge Group; Marshall Wace; Coastlands Capital; SilverArc Capital Management; Vestal Point Capital; Ausangate Capital
Use of proceeds: Advance preclinical cardiometabolic programs incl. IBIO-610 and IBIO-600, other pipeline assets, working capital and general corporate purposes
Aug 25, 2025
Warrant exercise of shares of common stock upon exercise of existing warrants
Announced: about US$6.2M · US$1.11 a share · Warrants at US$0.86 for 60 months · Chardan
Dealers: Chardan
Use of proceeds: Working capital and other general corporate purposes
Apr 29, 2025
Private placement of private placement offering
Closed: US$650,000 raised
Insiders: Private placement with members of its Board of Directors and Officers
Jan 13, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue100.0K400.0K225.0K01.88M2.37M1.64M2.02M444.0K394.0K
Cost of revenue1.03M1.25M1.11M216.0K1.46M703.0K13.0M13.0M
Gross profit100.0K400.0K225.0K50.0K2.17M909.0K935.0K2.02M444.0K394.0K
Research and development19.6M8.31M5.18M10.3M9.83M9.99M3.57M5.47M3.99M4.12M
Selling, general and administrative10.6M10.7M11.7M19.0M21.8M21.7M11.4M12.3M10.7M10.6M
Operating income-35.1M-18.6M-16.6M-29.3M-29.7M-31.1M-14.0M-15.8M-14.2M-14.3M
Depreciation and amortization558.0K484.0K638.0K674.0K2.27M472.0K282.0K179.0K1.37M1.33M
EBITDA-34.6M-18.1M-16.0M-28.7M-27.4M-30.6M-13.7M-15.6M-12.9M-12.9M
Interest expense53.0K212.0K172.0K83.0K1.41M2.45M2.47M1.90M1.92M1.93M
Income before tax-33.0M-18.4M-15.4M-29.3M-29.5M-23.2M-16.4M-17.6M-16.1M-14.5M
Income tax0000000000
Net income-33.0M-18.4M-24.9M-65.0M-50.3M-23.2M-16.4M-17.6M-16.1M-14.5M
Earnings per share, basic-0.32-1.75-6.50-106.19-5.78-3.00-0.61-0.94-1.54-1.64
Earnings per share, diluted-0.32-1.75-6.50-106.19-5.78-3.00-0.61-0.94-1.54-1.64

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents56.4M8.58M14.2M4.30M22.7M77.4M55.1M4.42M4.42M15.9M
Short-term investments31.6M00010.8M19.6M000
Receivables1.10M0001.00M426.0K75.0K97.0K75.0K175.0K
Inventory003.90M27.0K798.0K1026.0K
Current assets92.2M9.72M15.7M26.3M45.1M104.6M61.7M4.81M16.3M8.57M
Property, plant and equipment3.09M3.16M3.63M4.22M1.37M8.63M3.66M24.4M25.2M25.6M
Goodwill00
Total assets99.1M23.2M28.7M41.2M99.4M147.0M94.2M30.6M43.1M36.0M
Accounts payable4.42M2.19M358.0K1.85M4.26M2.25M1.76M1.00M790.0K749.0K
Current liabilities11.7M6.11M3.84M22.1M30.4M6.64M5.24M3.46M2.04M2.01M
Long-term debt766.0K339.0K24.9M25.1M
Total debt2.20M3.51M4.46M17.1M25.8M32.7M32.9M24.9M25.1M25.3M
Total liabilities13.4M8.30M7.41M25.8M35.9M38.4M37.6M28.1M26.9M27.1M
Shareholders' equity85.7M14.9M21.3M15.4M63.5M108.6M56.6M2.46M16.2M8.91M
Shares outstanding55.7M19.3M8.62M1.02M8.73M8.71M140.1M20.2M16.0M8.91M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-23.2M-15.3M-18.6M-30.4M-37.5M-30.1M-13.3M-14.0M-13.5M-13.2M
Capital spending-578.0K-16.0K-210.0K-5.74M-7.33M-4.92M-1.08M-920.0K-934.0K-1.32M
Free cash flow-23.8M-15.3M-18.8M-36.2M-44.8M-35.0M-14.4M-14.9M-14.4M-14.5M
Cash from investing-32.0M742.0K906.0K7.01M-5.13M-26.5M-1.15M-990.0K-1.08M-1.59M
Cash from financing103.0M8.93M24.5M2.30M-6.13M78.8M65.2M3.45M22.4M-170.0K
Dividends paid-500.0K-21.6M00
Share buybacks0-7.00K-39.0K0-40.8M-159.0K-125.0K0
Change in cash47.8M-5.63M6.85M-21.1M-48.7M22.3M50.7M-11.5M7.85M-14.9M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 20, 2026Current reportSEC
8-K · Current reportNov 16, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
8-K · Current reportOct 19, 2026Management or board changeSEC
4 · Change in ownershipOct 15, 2026Insider tradeSEC
4 · Change in ownershipOct 15, 2026Insider tradeSEC
4 · Change in ownershipOct 15, 2026Insider tradeSEC
4 · Change in ownershipOct 15, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 15, 2026Insider tradeSEC
4 · Change in ownershipOct 15, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 14, 2026Big-stake noticeSEC
8-K · Current reportOct 13, 2026Current reportSEC
8-K · Current reportSep 14, 2026Current reportSEC
ARS · Annual report to shareholdersSep 4, 2026Annual reportSEC
DEF 14A · Proxy statementSep 4, 2026Meeting noticeSEC
10-K · Annual reportAug 28, 2026Annual reportSEC
8-K · Current reportAug 28, 2026ResultsSEC
PRE 14A · Preliminary proxy statementAug 20, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 4, 2026Insider tradeSEC
8-K · Current reportAug 4, 2026Management or board changeSEC
8-K · Current reportJul 17, 2026Current reportSEC
8-K · Current reportJul 1, 2026Current reportSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
3 · Initial statement of ownershipMay 15, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
8-K · Current reportMay 8, 2026Management or board changeSEC
424B3 · ProspectusApr 29, 2026Offer documentSEC
8-K/A · Current report, amendedApr 17, 2026Current reportSEC
8-K · Current reportApr 8, 2026Current reportSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
8-K · Current reportMar 9, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveMar 9, 2026Other filingsSEC
424B5 · ProspectusMar 6, 2026Offer documentSEC
CORRESP · Letter to the SECMar 4, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 4, 2026Other filingsSEC
8-K · Current reportFeb 27, 2026Material contractSEC
S-3 · Registration statementFeb 27, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
10-Q · Quarterly reportFeb 10, 2026Quarterly reportSEC
8-K · Current reportFeb 10, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveFeb 10, 2026Other filingsSEC
424B3 · ProspectusFeb 9, 2026Offer documentSEC
CORRESP · Letter to the SECFeb 5, 2026Other filingsSEC
UPLOAD · Letter from the SECFeb 5, 2026Other filingsSEC
S-3 · Registration statementJan 30, 2026Offer documentSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 29, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 22, 2026Big-stake noticeSEC
DJan 22, 2026Other filingsSEC
8-K · Current reportJan 12, 2026Material contractSEC
SCHEDULE 13G · Big-stake noticeDec 19, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 17, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 16, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 3, 2025Big-stake noticeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
8-K · Current reportNov 21, 2025Meeting outcomeSEC
8-K · Current reportNov 17, 2025Current reportSEC
10-Q/A · Quarterly report, amendedNov 17, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
8-K · Current reportNov 4, 2025Current reportSEC
8-K · Current reportOct 30, 2025Current reportSEC
4 · Change in ownershipOct 22, 2025Insider tradeSEC
4 · Change in ownershipOct 22, 2025Insider tradeSEC
4 · Change in ownershipOct 22, 2025Insider tradeSEC
ARS · Annual report to shareholdersOct 6, 2025Annual reportSEC
DEF 14A · Proxy statementOct 6, 2025Meeting noticeSEC
10-K · Annual reportSep 5, 2025Annual reportSEC
8-K · Current reportSep 5, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 26, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 25, 2025Big-stake noticeSEC
8-K · Current reportAug 21, 2025Material contractSEC
424B5 · ProspectusAug 21, 2025Offer documentSEC
8-K · Current reportAug 18, 2025ResultsSEC
424B5 · ProspectusAug 18, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
8-K · Current reportAug 1, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 30, 2025Big-stake noticeSEC
424B3 · ProspectusJun 24, 2025Offer documentSEC
8-K · Current reportJun 24, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveJun 24, 2025Other filingsSEC
CORRESP · Letter to the SECJun 18, 2025Other filingsSEC
UPLOAD · Letter from the SECJun 18, 2025Other filingsSEC
8-K · Current reportJun 18, 2025Current reportSEC
S-3 · Registration statementJun 13, 2025Offer documentSEC
DMay 7, 2025Other filingsSEC
10-Q · Quarterly reportMay 2, 2025Quarterly reportSEC
8-K · Current reportMay 2, 2025ResultsSEC
424B5 · ProspectusApr 30, 2025Offer documentSEC
424B5 · ProspectusApr 30, 2025Offer documentSEC
424B5 · ProspectusApr 30, 2025Offer documentSEC
8-K · Current reportApr 22, 2025Material contractSEC
8-K · Current reportApr 8, 2025Current reportSEC
8-K · Current reportApr 7, 2025Current reportSEC
25Mar 3, 2025Other filingsSEC
CERT · Exchange's certificate of listingMar 3, 2025Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeMar 3, 2025Other filingsSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
8-K · Current reportFeb 19, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
424B3 · ProspectusFeb 11, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 11, 2025Other filingsSEC
10-Q · Quarterly reportFeb 10, 2025Quarterly reportSEC
8-K · Current reportFeb 10, 2025ResultsSEC
CORRESP · Letter to the SECFeb 7, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 6, 2025Other filingsSEC
S-8 · Registration statement for employee plansJan 31, 2025Offer documentSEC
S-3 · Registration statementJan 31, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 29, 2025Big-stake noticeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
8-K · Current reportJan 13, 2025Material contractSEC
8-K · Current reportJan 10, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 3, 2025Big-stake noticeSEC
8-K · Current reportJan 2, 2025Material contractSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
3 · Initial statement of ownershipDec 9, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 25, 2024Insider tradeSEC
8-K · Current reportNov 25, 2024ResultsSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
8-K · Current reportOct 23, 2024Current reportSEC
ARS · Annual report to shareholdersOct 10, 2024Annual reportSEC
DEF 14A · Proxy statementOct 10, 2024Meeting noticeSEC
10-K/A · Annual report, amendedSep 24, 2024Annual reportSEC
10-K · Annual reportSep 20, 2024Annual reportSEC
8-K · Current reportSep 20, 2024ResultsSEC
3 · Initial statement of ownershipAug 14, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 7, 2024Other filingsSEC
424B5 · ProspectusAug 6, 2024Offer documentSEC
CORRESP · Letter to the SECAug 2, 2024Other filingsSEC
8-K · Current reportJul 26, 2024Management or board changeSEC
CORRESP · Letter to the SECJul 25, 2024Other filingsSEC
S-3/A · Registration statement, amendedJul 25, 2024Offer documentSEC
UPLOAD · Letter from the SECJul 18, 2024Other filingsSEC
8-K · Current reportJul 9, 2024Management or board changeSEC
8-K · Current reportJul 3, 2024Material contractSEC
S-3 · Registration statementJul 3, 2024Offer documentSEC
8-K · Current reportJun 5, 2024Acquisition or disposalSEC
8-K · Current reportJun 3, 2024Current reportSEC
8-K · Current reportMay 20, 2024Material contractSEC
4 · Change in ownershipMay 13, 2024Insider tradeSEC
4 · Change in ownershipMay 13, 2024Insider tradeSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
8-K · Current reportMay 13, 2024ResultsSEC
4 · Change in ownershipApr 26, 2024Insider tradeSEC
424B3 · ProspectusApr 25, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 25, 2024Other filingsSEC
CORRESP · Letter to the SECApr 22, 2024Other filingsSEC
UPLOAD · Letter from the SECApr 22, 2024Other filingsSEC
S-3 · Registration statementApr 16, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedApr 9, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeApr 8, 2024Big-stake noticeSEC

This page holds 200 of 914 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from iBio, Inc.’s releases · as of Sep 30, 2026

Common shares
64,307,256
Fully diluted
64,307,256

Fully diluted

LineSharesAs of
Common shares64,307,256Sep 30, 2026

Warrants and options

Lot
Warrants · US$0.70 · expiry not stated

Share count over time

CountShares
Sep 30, 202664,307,256

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Silverarc Capital Management, LLC5.36M8.3%US$6.32MSep 30, 2026
Affinity Asset Advisors, LLC4.13M6.4%US$4.87MSep 30, 2026
Cormorant Asset Management, LP3.57M5.6%US$4.21MSep 30, 2026
Vestal Point Capital, LP2.6M4.0%US$3.07MSep 30, 2026
Vanguard2.42M3.8%US$2.85MSep 30, 2026
Woodline Partners LP2.24M3.5%US$2.64MSep 30, 2026
Frazier Life Sciences Management, L.P.1.95M3.0%US$2.31MSep 30, 2026
Balyasny Asset Management L.P.1.59M2.5%US$1.88MSep 30, 2026
Ensign Peak Advisors, Inc1.57M2.4%US$1.85MSep 30, 2026
Bank of America1.49M2.3%US$1.76MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Millennium1.42M2.2%US$1.68MSep 30, 2026
Ikarian Capital, LLC957K1.5%US$1.13MSep 30, 2026
Sio Capital Management, LLC904K1.4%US$1.07MSep 30, 2026
Atom Investors LP882K1.4%US$1.04MSep 30, 2026
Marshall Wace, LLP766K1.2%US$904KSep 30, 2026
Renaissance Technologies688K1.1%US$812KSep 30, 2026
Citadel666K1.0%US$786KSep 30, 2026
Geode Capital526K0.82%US$621KSep 30, 2026
Walleye Capital LLC400K0.62%US$472KSep 30, 2026
ADAR1 Capital Management, LLC376K0.58%US$443KSep 30, 2026
Sofinnova Investments, Inc.372K0.58%US$439KSep 30, 2026
BlackRock291K0.45%US$344KSep 30, 2026
Boothbay Fund Management, LLC254K0.40%US$300KSep 30, 2026
Noesis Capital Mangement Corp249K0.39%US$294KSep 30, 2026
Two Sigma240K0.37%US$284KSep 30, 2026
State Street219K0.34%US$258KSep 30, 2026
Goldman Sachs200K0.31%US$236KSep 30, 2026
Verdad Advisers, LP197K0.31%US$232KSep 30, 2026
DAFNA Capital Management LLC170K0.26%US$201KSep 30, 2026
XTX Topco Ltd165K0.26%US$195KSep 30, 2026
Morgan Stanley126K0.20%US$149KSep 30, 2026
Squarepoint Ops LLC112K0.17%US$132KSep 30, 2026
Northern Trust111K0.17%US$131KSep 30, 2026
Hrt Financial LP92,6760.14%US$109KSep 30, 2026
Landscape Capital Management, L.L.C.88,7960.14%US$105KSep 30, 2026
UBS30,3280.05%US$35,787Sep 30, 2026
R Squared Ltd24,1530.04%US$28,501Sep 30, 2026
Readystate Asset Management LP21,6940.03%US$25,599Sep 30, 2026
Spark Investment Management LLC17,6000.03%US$20,768Sep 30, 2026
StoneX Group Inc.16,0870.03%US$22,522Sep 30, 2026
Innovative Asset Advisors Group, LLC15,0000.02%US$17,700Sep 30, 2026
BNY10,6360.02%US$12,551Sep 30, 2026
JPMorgan1,436<0.01%US$1,680Sep 30, 2026
Tower Research Capital LLC (TRC)1,224<0.01%US$1,444Sep 30, 2026
RBC1,194<0.01%US$1,000Sep 30, 2026
Fortitude Family Office, LLC431<0.01%US$509Sep 30, 2026
Osaic Holdings, Inc.380<0.01%US$448Sep 30, 2026
Fidelity220<0.01%US$260Sep 30, 2026
Caitong International Asset Management Co., Ltd60<0.01%US$71Sep 30, 2026
SHP Wealth Management60<0.01%US$105Sep 30, 2026

This page holds 50 of 60 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.47M2.3%US$2.57MJun 30, 2026
Vanguard Extended Market Index Fund582K0.91%US$1.02MJun 30, 2026
Fidelity Extended Market Index Fund188K0.29%US$357KMay 31, 2026
iShares Micro-Cap ETF104K0.16%US$182KJun 30, 2026
Fidelity Total Market Index Fund63,8030.10%US$121KMay 31, 2026
Fidelity Series Total Market Index Fund51,3450.08%US$97,556May 31, 2026
Vanguard Institutional Total Stock Market Index Fund29,5860.05%US$51,776Jun 30, 2026
Vanguard Balanced Index Fund20,6610.03%US$36,157Jun 30, 2026
Fidelity Nasdaq Composite Index Fund19,4350.03%US$36,927May 31, 2026
1290 VT Micro Cap Portfolio6,9700.01%US$12,198Jun 30, 2026
All 12 holders
HolderSharesOf the companyValueAs of
Total Stock Market Index Trust654<0.01%US$1,145Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund500<0.01%US$875Jun 30, 2026

Big stakes

StakeStakeSharesDateFiling
Cormorant Asset Management, LP9.99%5.12MJun 30, 2026Schedule 13G
Affinity Asset Advisors, LLC9.99%5.07MJun 30, 2026Schedule 13G
Silverarc Capital Management, LLC9.99%2.18MSep 30, 2025Schedule 13G
Adage Capital Management, L.P.9.99%2.18MSep 30, 2025Schedule 13G
Sirenia Capital Management LP9.90%11.6MMar 31, 2026Schedule 13G
Coastlands Capital LP9.72%6.25MOct 7, 2026Schedule 13G
Vestal Point Capital, LP7.90%4.03MJun 30, 2026Schedule 13G
Opaleye Management Inc.7.60%750KDec 31, 2024Schedule 13G
Lynx1 Capital Management LP5.40%2.81MJun 30, 2026Schedule 13G
Integrated Core Strategies (US) LLC5.20%1.23MJan 15, 2026Schedule 13G
All 11 stakes
StakeStakeSharesDateFiling
Frazier Life Sciences Public Fund, L.P.3.00%1.95MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Evert Schimmelpennink
Other companies: Contineum Therapeutics, Inc. (President, LENZ Therapeutics · Since at least Apr 4, 2024); LENZ Therapeutics, Inc. (President, Chief Executive Officer, Secretary and Director · Since at least Mar 21, 2024); Pfenex Inc (See Remarks, Director · Oct 1, 2020 – Oct 1, 2020 · Past)
Director · Since at least Jun 7, 2021
Elizabeth Stoner
Other companies: Radius Health, Inc. (Director · Dec 17, 2014 – Dec 17, 2014 · Past); Momenta Pharmaceuticals Inc (Director · Jun 11, 2013 – Oct 1, 2020 · Past)
Director · Since at least May 7, 2026
Alexandra Kropotova
Other companies: SAB Biotherapeutics, Inc. (CHIEF MEDICAL OFFICER · Since at least Mar 27, 2025)
Director · Since at least Nov 20, 2025
Chip Clark
Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least Apr 17, 2025)
Chairman of the Board · Since at least Nov 5, 2026
John Delta
Other companies: Motorsport Games Inc. (Director · Since at least Oct 4, 2022)
Principal Accounting Officer · Oct 1, 2020 – Oct 1, 2020 · Past
Jules A Musing
Other companies: TherapeuticsMD, Inc. (Director · May 16, 2013 – Sep 29, 2022 · Past)
Director · Feb 1, 2012 – Jul 24, 2012 · Past
William D Clark
Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least Apr 17, 2025)
Director · Since at least Nov 21, 2024
António ParadaDirector · Since at least Feb 10, 2025
David ArkowitzDirector · Since at least Feb 10, 2025
Endocrinologist Molly CarrChief Medical Officer · Since at least Aug 4, 2026
All 19 people
PersonSeat
Felipe DuranChief Financial Officer · Since at least Nov 2, 2026
Gary SenderDirector · Since at least Nov 5, 2026
Glenn ChangDirector · Feb 20, 2019 – Dec 9, 2021 · Past
Hill James T GeneralDirector · Dec 9, 2021 – Dec 9, 2021 · Past
Marc BanjakChief Legal Officer · Since at least Aug 14, 2024
Martin BrennerChief Executive Officer and Chief Scientific Officer · Since at least Nov 2, 2026
Molly CarrChief Medical Officer · Since at least Jul 31, 2026
Philip K RussellDirector · Feb 20, 2019 – Apr 1, 2019 · Past
Ryan E TerenceChief Scientific Officer · Feb 20, 2019 – Feb 20, 2019 · Past

Open People

Log in to ask 6ix AI your own questions about iBio, Inc.